Safety of Liraglutide in Subjects With Liver Impairment and in Subjects With Normal Liver Function

NCT01507389 · Completed

Last updated 2026-05-28

This clinical trial tested the safety of the medication liraglutide in adults with type 2 diabetes who have liver impairment compared to those with normal liver function.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Non-randomized, open-label (no blinding) treatment study

Participants 24 people

Who can join Ages 18–75 · all sexes Healthy volunteers accepted.

Timeline Started 2006-03 · est. completion 2006-06

Where 1 site · Poland

What this study is testing ClinicalTrials.gov NCT01507389 ↗

Description as written by the study sponsor.

This trial is conducted in Europe. The aim of this trial is to investigate liraglutide in subjects with mild, moderate and severe degrees of hepatic impairment compared with subjects with normal hepatic function.

Treatments tested

liraglutide Drug

Single dose of 0.75 mg injected subcutaneously (under the skin)

Main thing measured	Area under the Curve (0-infinity)
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01507389 ↗